Literature DB >> 19947842

Economic evaluation of pharmacotherapy of migraine pain: a review of the literature.

Junhua Yu1, Michael J Goodman, Gary M Oderda.   

Abstract

This paper reviews the economic evaluation literature on pharmacotherapy for migraine and identifies important trends and gaps in the literature. Given the tremendous economic burden of migraine and the availability of various therapies for migraine treatment, economic evaluation of alternative therapies plays a critical role in identifying the most cost-effective therapy to optimize health care resource allocation and clinical decisions. Particularly, physicians and clinical administrators are expected to take an active role in resource allocation decisions at the clinical level. Thus, it is important for them to be familiar with the economic evaluation in migraine pain management, and most importantly, methodologies of economic analyses and the associated shortcomings of published estimates. In this paper, the methodological characteristics of these studies are examined and their results are compared and interpreted. Alternative treatment and health outcome measures are defined and data sources described while methods for assessing the direct and indirect costs are explored. Directions for future research are identified and discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19947842     DOI: 10.3109/15360280903328185

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  5 in total

1.  Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review.

Authors:  Matteo Ruggeri; Carlo Drago; Francesco Rosiello; Valentina Orlando; Costanza Santori
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

2.  Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries.

Authors:  Mattias Linde; Timothy J Steiner; Dan Chisholm
Journal:  J Headache Pain       Date:  2015-02-18       Impact factor: 7.277

Review 3.  A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.

Authors:  Saval Khanal; Martin Underwood; Seyran Naghdi; Anna Brown; Callum Duncan; Manjit Matharu; Hema Mistry
Journal:  J Headache Pain       Date:  2022-09-16       Impact factor: 8.588

4.  Economic impact of a triptan Rx-to-OTC switch in six EU countries.

Authors:  Aurelie Millier; Joshua Cohen; Mondher Toumi
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

5.  A universal outcome measure for headache treatments, care-delivery systems and economic analysis.

Authors:  Timothy J Steiner; Mattias Linde; Petra Schnell-Inderst
Journal:  J Headache Pain       Date:  2021-07-01       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.